Full-Time

Senior Scientist

CMC Quality Control

City Therapeutics

City Therapeutics

51-200 employees

Develops RNAi therapeutics using trigger molecules

Compensation Overview

$136k - $154k/yr

+ Annual cash bonus + Equity compensation

Cambridge, MA, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Ph.D. in Analytical Chemistry or related field with 3+ years relevant industry experience; M.S. with 7+ years; or B.S. with 10+ years.
  • Strong AX-HPLC and HPLC–MS technical background with hands-on oligonucleotide analysis experience.
  • Proven understanding of analytical instrumentation theory and practice across Drug Substance/Drug Product development and manufacturing processes.
  • Demonstrated skills in handling, analyzing, and characterizing oligonucleotides and related organic molecules.
  • Familiarity with cGxP expectations, analytical data systems, and data integrity principles.
  • Meticulous documentation, strong problem-solving, and the ability to operate with minimal supervision.
  • Excellent communication, organization, and teamwork skills; comfortable in a fast-paced, multi-project environment with shifting priorities.
Responsibilities
  • Lead method verification/qualification, validation (as needed), and method transfer for existing and new programs.
  • Manage stability protocols and reports from partners.
  • Conduct exploratory stability studies for raw materials, intermediates, DS, and DP; interpret trends and recommend actions.
  • Work both independently and with cross-functional teams to plan, prioritize, and meet project timelines.
  • Write CMC source documents such as, but not limited to, analytical methods, qualification/validation protocols and reports.
  • Operate, calibrate, maintain, and troubleshoot analytical instrumentation; ensure adherence to data integrity and safety practices.
Desired Qualifications
  • CDMO experience is highly valued.
  • Knowledge of CMC regulatory requirements (e.g., IND/IMPD) is a plus.
  • Understanding of basic theories and principles of synthetic organic chemistry is a plus.

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Company Size

51-200

Company Stage

Series A

Total Funding

$135M

Headquarters

Massachusetts

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Biogen CNS partnership yields $16M upfront and $1B milestones.
  • CITY-FXI Phase 1 trial yields data late 2026 for thromboembolism.
  • $135M Series A funds pipeline through 2026 IND cadence.

What critics are saying

  • Alnylam erodes edge with superior GalNAc siRNAs in 12-24 months.
  • Silence SLN360 Phase 2 captures Factor XI market in 18-24 months.
  • Cash burns $135M by mid-2027 without Series B funding.

What makes City Therapeutics unique

  • Next-generation cityRNA triggers enable extra-hepatic tissue targeting beyond liver.
  • Co-founded by Alnylam veterans like John Maraganore for RNAi expertise.
  • Proprietary siRNA engineering expands RNAi to CNS and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at City Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Life Insurance

Disability Insurance

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Company News

Business Wire
Oct 8th, 2024
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer Dr. John Maraganore